Patient-reported outcomes: The example of health-related quality of life - A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process

Drug Information Journal

Volumn 36, Issue 1, 2002, Pages 209-238

  Chassany, Olivier ^a   Sagnier, Pierre ^a   Marquis, Patrick ^a   Fullerton, Steve ^a   Aaronson, Neil ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Guidelines; Health related quality of life (HRQOL); Missing data; Patient reported outcomes; Randomized clinical trials

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECISION MAKING; DRUG INFORMATION; EVALUATION; FUNCTIONAL ASSESSMENT; HUMAN; INSTRUMENT; MEDICAL LITERATURE; OUTCOMES RESEARCH; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0036185590     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150203600127     Document Type: Article

References (112)

1. Food and Drug Administration requirements for approval of new anticancer drugs
2. Evaluating quality-of-life and health status instruments: Development of scientific review criteria
3. Instrument review criteria
4. Guidelines for reporting results of quality of life assessments in clinical trials
5. Quality of life assessment in clinical trials - Guidelines and a checklist for protocol writers: The UK Medical Research Council experience
6. Recommendations for evaluating the validity of quality of life claims for labeling and promotion
7. Quality of life studies from the perspective of an FDA reviewing statistician
8. Reporting on quality of life in randomised controlled trials: Bibliographic study
9. Reporting on quality of life in randomised controlled trials
10. Methodologic assessments of quality of life measures in clinical trials
11. Strategies and pitfalls in quality of life research
12. Quality of life evaluation in oncological clinical trials - The EORTC model
13. Does dehydroepiandrosterone improve well-being?
14. Definition and conceptual issues
15. State of science 1986: Quality of life and functional status as target variables for research
16. How to assess quality of life in medicine: Rationale and methods
17. Acceptable evidence for pharmaceutical advertising and labeling
18. Quality of life assessment in clinical trials: Methodologic issues
19. Assessment of quality of life outcomes
20. Health-related quality-of-life assessment and planning for the pharmaceutical industry
21. Clinimetric perspectives
22. The measurement of quality of life in hypertensive patients: A practical approach
23. Factors of importance when evaluating quality of life in clinical trials
24. Aspects of quality of life in gastrointestinal disease: Some methodological issues
25. Quality of life scores correlate poorly with subjective and objective measurements of gastroesophageal reflux
26. How should we measure function in patients with chronic heart and lung disease?
27. Patients' self-assessment of their cognitive heart failure: II: Content, reliability and validity of a new measure. The Minnesota Living with Heart Failure Questionnaire
28. Measuring quality of life in asthma
29. The relationship between exercise tolerance and quality of life in angina pectoris
30. Measuring health-related quality of life
31. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study
32. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C
33. Breast cancer survivors: Psychological concerns and quality of life
34. Quality of life measures in health care. II: Design, analysis, and interpretation
35. A critical appraisal of the quality of quality of life measurements
36. Generic and disease-specific measures in assessing health status and quality of life
37. Prospective randomized controlled trial of respiratory rehabilitation
38. Analysis of quality of life data from a randomized, placebo controlled heart-failure trial
39. The use of generic and specific quality-of-life measures in hemodialysis patients treated with Erythropoietin
40. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of Omeprazole and Cisapride
41. Quality of life before and after orthotopic hepatic transplantation
42. Validation of a specific quality of life questionnaire in Functional Digestive Disorders (FDDQL)
43. Health status measures: An overview and guide for selection
44. Quality of life and regulatory issues
45. Methods for quality-of-life studies
46. Measuring health status: What are the necessary measurement properties?
47. Assessing reliability and validity of measurement in clinical trials
48. Quality-of-life measurements in the evaluation of treatment: Proposed guidelines
49. Psychometric properties of a specific quality of life questionnaire in angina pectoris patients
50. Sensitivity to change of weighted and unweighted versions of two health status measures
51. Weighted versus unweighted life event scores: Is there a difference?
52. Quality of life measures in health care. I: Applications and issues in assessment
53. A methodologic framework for assessing health indices
54. A new measure of health status for clinical trials in inflammatory bowel disease
55. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument
56. Physical and psychological correlates of functioning in patients with chronic obstructive pulmonary disease
57. Coping, distress, and survival among patients with lung cancer
58. Convergent, discriminative, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with Analogous Scales Form the EORTC QLQ-C30 and a trial-specific module
59. Low-dose Cyclosporine for the treatment of Crohn's Disease
60. Measuring health status over time. Assessing the usefulness of evaluative instruments
61. Effect sizes for interpreting changes in health status
62. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation
63. Languages and translation issues
64. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models
65. Cross-cultural issues in the use of quality of life measures in randomized clinical trials
66. Translating health status questionnaires and evaluating their quality: The IQOLA project approach. International Quality of Life Assessment
67. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines
68. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA project
69. Quality of life trials
70. Missing quality data in cancer clinical trials: Serious problems and challenges
71. Rationale for the timing of health-related quality-of-life assessments in oncological palliative therapy
72. The validity of proxy-generated scores as measures of patient health status
73. The use of significant others as proxy raters of the quality of life of patients with brain cancer
74. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review
75. Assessment of quality of life by patient and spouse during antihypertensive therapy with Atenolol and Nifedipine gastrointestinal therapeutic system
76. Use of the health utilities index with stroke patients and their caregivers
77. Value of caregiver ratings in evaluating the quality of life of patients with cancer
78. Assessing quality of life after stroke. The value and limitations of proxy ratings
79. Randomized trials with quality of life endpoints. Are doctor's ratings of patients' physical symptoms interchangeable with patients' self-ratings?
80. Practical approaches to minimize problems with missing quality of life data
81. Clinical significance of quality of life data
82. Ethics and clinical trials
83. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: A clinical experience network (CEN) Study
84. Quality of life questionnaires: Does statistically significant = clinically important?
85. Interpretation of quality of life changes
86. Measurement of the quality of life in clinical trials: In pursuit of the unapproachable
87. Analysis of incomplete quality of life data in clinical trials
88. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials
89. Pitfalls in quality of life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial
90. Compliance with QoL assessment in multicentre German breast cancer trials
91. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)
92. Suggestions for the presentation of quality of life data from clinical trials
93. Statistical analysis of quality of life with missing data in cancer clinical trials
94. Quality of life: Statistical issues and analysis
95. Interpreting treatment effects in randomised trials
96. Measurement of health status: Ascertaining the minimal clinically important difference
97. Interpreting the significance of changes in health-related quality-of-life scores
98. Determining a minimal important change in a disease-specific quality of life questionnaire
99. The effect of Fluticasone Propionate on functional status and sleep in children with asthma and on the quality of life of their parents
100. Determining clinically important differences in health status measures
101. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life
102. The cost effectiveness of Auranofin: Results of a randomized clinical trial
103. Interpreting general health measures
104. The number needed to treat: A clinically useful measure of treatment effect
105. Confidence intervals for the number needed to treat
106. The value of quality of life in asthma
107. The effects of Naftidrofuryl on quality of life
108. Absence of evidence is not evidence of absence